To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
Developing Differentiated Immunology Solutions
Science is only the starting point. argenx translates deep immunology expertise into medicines that don’t just treat disease—they target areas with few or no options.
At the forefront of autoimmune disease research, argenx engineers first-in-class therapies where the need is greatest, where breakthroughs can change lives, and where bold science is the only path forward.
Our franchise-focused development model has built a pipeline as broad as it is deep. We advance the most promising programs in-house, and partner with others to maximize reach and impact.
Our Pipeline
No results
*Approved for all gMG serotypes: anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative
Preclinical Pipeline Candidates
These candidates represent our next generation of differentiated immunology solutions. Each discovered through our pursuit of science unbound.
No results
Proven Immunology Innovation Program Impact
argenx has several assets that emerged from the Immunology Innovation Program (IIP) that have been out-licensed to a partner for further development.
Target: IL-22R
LEO Pharma is a global pharmaceutical company specializing in dermatology. ARGX-112 (LP0145) was designed as a SIMPLE AntibodyTM to block IL22R, a receptor that drives inflammatory activity in the skin. LEO Pharma is evaluating this antibody as a potential treatment for atopic dermatitis.
Target: MET
Agomab Therapeutics is a biotechnology company focused on regenerative medicine. ARGX-114 (now AGMB-101) was developed from argenx’s SIMPLE AntibodyTM platform to target the MET receptor, which plays a vital role in tissue repair and regeneration. Agomab is advancing this antibody as a potential therapy for patients living with fibrotic, inflammatory, autoimmune, and degenerative diseases.
Target: GARP
AbbVie is a global biopharmaceutical company with expertise spanning oncology, immunology, and neuroscience. ARGX-115 (now ABBV-151) is a SIMPLE AntibodyTM designed to block GARP, a protein that enables tumors to suppress immune responses. AbbVie is investigating this antibody for its potential to reactivate the immune system against cancer.
Externally Sponsored Research
We believe in accelerating discovery processes to bring solutions to patients through innovative and collaborative science-driven research.
Externally Sponsored Research (ESR) can lead to meaningful advances in disease understanding and treatment.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
ARGX-118
Designed around the first novel airway inflammation target identified in decades.
Efgartigimod
The science and data behind our first-in-class FcRn-targeting antibody for long-overlooked diseases.
Partnered Program Success
See how IIP-born assets move forward with the right partners.
